β-Gal / β-Galactosidase antibody for ADC (isotype control)

Monoclonal human IgG1 antibody against β-galactosidase for antibody-drug conjugation

InvivoGen provides Anti-β-Gal-hIgG1*, a monoclonal antibody (mAb) specifically developed for the generation of control antibody-drug conjugates (ADCs). This mAb features:

• the variable region of a murine mAb which specifically targets the E. coli β-galactosidase (β-Gal),
• a human IgG1 constant region that displays high effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC).

InvivoGen's Anti-β-Gal-hIgG1* has been generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography.

Key features of Anti-β-Gal-hIgG1*:

• No binding to any other antigen than β-Gal, as verified by ELISA, flow cytometry, and ADC-based cellular assays
• Human IgG1 constant region for high effector functions
• The absence of bacterial contamination has been confirmed

Application for Anti-β-Gal-hIgG1*:

• Negative control for ADC-based assays
   

InvivoGen offers Anti-HER2-IgG1 and Anti-TROP2-hIgG1 specific mAbs, as well as conjugatable PRR ligands for building immunostimulatory ADCs.
You may choose from TLR7 and STING agonists:
- Conjugatable TLR7 agonists: TL7-887 and TL7-975
- Conjugatable STING agonists: STG-982 and STG-968

Learn more about bioconjugation